Copenhagen, Capital Region of Denmark, Denmark
I build technology that reads the proteome directly from a patient's tissue — by cell phenotype, in spatial context. It connects what a pathologist sees under the microscope to the molecular programs that drive disease, beyond what DNA and RNA can show. At Resolute Bio (formerly OmicVision Biosciences) I am Co-Founder and CSO. We are a molecular intelligence company: our platform pairs deep-learning computational pathology with high-resolution mass spectrometry to generate high-throughput spatial proteomics data from patient tissue across oncology, neurology, and chronic disease. We use those data to find emergent biology, train machine-learning models, and build the next generation of personalized medicine. DVP — the scientific foundation — was published in Nature Biotechnology (2022). We recently used it to map how pancreatic cancer begins: lesions that look identical under the microscope are already molecularly different long before cancer is visible — a protein signature that could flag which patients will progress, and a basis for early detection in a disease with ~12% five-year survival (Cancer Discovery, 2026). In parallel I hold a tenured Associate Professorship in Clinical Proteomics at the University of Copenhagen, leading an international network applying DVP to patient tissue. Twitter/X @MundAndreas · @labs_mann · @OmicVision Translating the code of life — turning proteomic data into clinical gold.
Co-founded a molecular intelligence company built on Deep Visual Proteomics — generating high-throughput spatial proteomics data from patient tissue across oncology, neurology, and chronic disease. ▪ Define the scientific strategy and platform roadmap — a molecular intelligence platform ResOne that pairs deep-learning computational pathology with high-resolution mass spectrometry. ▪ Lead the consortium for TIP-PDAC, an Innovation Fund Denmark Grand Solutions project building a pancreatic-cancer tissue and plasma biomarker program for early detection and recurrence monitoring with US academic and clinical partners. ▪ Partner with pharma, hospitals, and academic groups to translate tissue-level proteomic signatures into biomarkers and drug targets, and to train machine-learning models for precision medicine. ▪ Build the team, lab, and mass-spectrometry capability behind the platform.
Lead an interdisciplinary international research network developing and applying Deep Visual Proteomics to patient tissue. ▪ Co-developed Deep Visual Proteomics, combining AI image analysis, laser microdissection, and ultra-high-sensitivity mass spectrometry to profile the proteome of defined cell types in spatial context (Nature Biotechnology, 2022). ▪ Apply DVP to clinical FFPE samples at high sensitivity from very low cell numbers, building spatially-resolved proteomic maps of cancer progression. ▪ Chair the appointment committee for PhD and postdoc positions at the center. ▪ Teach proteomics, new methods, and omics for clinical researchers at master's and PhD level. Mentor: Prof. Matthias Mann
o Provide advice on the strategic direction and troubleshoot any significant problems.
Advisors: Hans Will/Thomas Dobner, Viral Transformation Unit o Identified and characterized novel gene regulatory mechanisms mediated by protein complexes that signal through chromatin modulating factors that mediate the antiviral host cell response. o Authored three research articles published in J Virol., PloS Pathog., and NAR. o Obtained the Jung Foundation for Science and Research Travel Award (7,500 Kr).
Advisor: Hans Will, General Virology Unit o Identified and characterized a novel epigenetic reader and regulator of the DNA damage response and repair with implication in carcinogenesis. o Authored two (first)-author research articles published in NAR and eLife. o Obtained the GlaxoSmithKline Foundation & Funding of Science and Research at the University of Hamburg/ Foundation and Corporate Funds Travel Award (15,000 Kr.)
Advisor: Hans Will, General Virology Unit o Research focused on analysis of PML bodies in Hepatitis B Virus infected and non-infected liver cells.